Business Description
Immatics N.V. is a Germany-based company working to develop new cancer treatments that harness the power of the immune system, with a particular focus on hard-to-treat solid tumors. The company is advancing several therapies through clinical trials, including cell-based treatments and a class of precision proteins designed to direct immune cells toward cancer. To support its research, Immatics has formed partnerships with leading organizations such as MD Anderson Cancer Center, Celgene, and Genmab.
